What Is Harmony Biosciences Holdings, I (HRMY) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Harmony Biosciences Holdings, I presents a highly debated valuation profile at its current price of $35.54. The composite intrinsic value is estimated at $54.21 (+52.5% average upside), masking a wide model spread between the 6 bullish models and 4 bearish models. Model dispersion is worth noting: Markov DDM targets $202.71 (+470.4%), versus Dynamic NAV at $14.05 (-60.5%). This +530.8% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About HRMY?
13 of 13 models are currently active for HRMY. Of these, 6 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates HRMY's intrinsic value at $82.06, implying +130.9% upside from the current price. See which stocks rank higher →
How Does HRMY Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, HRMY ranks #3 by Quality of Company score. CirclFi's QOC score of 10.0/10 evaluates 32 fundamental signals. A score of 10.0 places HRMY in the top tier.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to biopharma enterprise businesses. For Harmony Biosciences Holdings, I, metrics like revenue per drug provide important context that general-purpose valuation models may underweight.
Is HRMY a Value Trap?
CirclFi's Value Trap algorithm assigns HRMY a score of 20/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for Harmony Biosciences Holdings, I. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Harmony Biosciences Holdings, I scores 10.0 out of 10 on our 32-signal quality assessment, a elite rating that ranks among the highest-quality businesses in our coverage universe. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +530.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every HRMY valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across HRMY's 13 active models, average confidence is 42%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad